Prophylactic probiotics for cancer therapy-induced diarrhoea: A meta-analysis

Current Opinion in Supportive and Palliative Care

Volumn 12, Issue 2, 2018, Pages 187-197

  Wardill, Hannah R ^a,b   Van Sebille, Ysabella Z A ^c   Ciorba, Matthew A ^d   Bowen, Joanne M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer therapy; chemo radiotherapy; diarrhoea; meta analysis; probiotics

Indexed keywords

ANTINEOPLASTIC AGENT; PROBIOTIC AGENT;

CHEMICALLY INDUCED; DIARRHEA; HUMAN; META ANALYSIS; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTINEOPLASTIC AGENTS; DIARRHEA; HUMANS; NEOPLASMS; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85046799692     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000338     Document Type: Review

References (43)

1. Cinausero M, Aprile G, Ermacora P, et al. New frontiers in the pathobiology and treatment of cancer regimen-related mucosal injury. Front Pharmacol 2017; 8:354.
2. Andreyev J, Ross P, Donnellan C, et al. Guidance on the management of diarrhoea during cancer chemotherapy. The Lancet Oncology 2014; 15:e447-460.
3. Hoff PM, Saragiotto DF, Barrios CH, et al. Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapyinduced diarrhea in patients with colorectal cancer: the LARCID trial. J Clin Oncol 2014; 32:1006-1011.
4. Thaiss CA, Zmora N, Levy M, Elinav E. The microbiome and innate immunity. Nature 2016; 535:65-74.
5. Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol 2017; 14:356-365.
6. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277-284.
7. Montassier E, Batard E, Massart S, et al. 16S rRNA gene pyrosequencing reveals shift in patient faecal microbiota during high-dose chemotherapy as conditioning regimen for bone marrow transplantation. Microb Ecol 2014; 67:690-699.
8. Montassier E, Gastinne T, Vangay P, et al. Chemotherapy-driven dysbiosis in the intestinal microbiome. Aliment Pharmacol Ther 2015; 42:515-528.
9. Nam YD, Kim HJ, Seo JG, et al. Impact of pelvic radiotherapy on gut microbiota of gynecological cancer patients revealed by massive pyrosequencing. PLoS One 2013; 8:e82659.
10. Wang A, Ling Z, Yang Z, et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One 2015; 10:e0126312.
11. Ciorba MA, Hallemeier CL, Stenson WF, Parikh PJ. Probiotics to prevent gastrointestinal toxicity from cancer therapy: an interpretive review and call to action. Curr Opin Support Palliat Care 2015; 9:157-162.
12. Packey CD, Ciorba MA. Microbial influences on the small intestinal response to radiation injury. Curr Opin Gastroenterol 2010; 26:88-94.
13. Ciorba MA. Chapter 41-the prevention and treatment of radiation and chemotherapy-induced intestinal mucositis A2-Floch, Martin H. In: Ringel Y, Walker WA, editors. The Microbiota in Gastrointestinal Pathophysiology. Boston, MA: Academic Press; 2017. pp. 383-387.
14. Bowen JM, Stringer AM, Gibson RJ, et al. VSL#3 probiotic treatment reduces chemotherapy-induced diarrhea and weight loss. Cancer Biol Ther 2007; 6:1449-1454.
15. Demirer S, Aydintug S, Aslim B, et al. Effects of probiotics on radiationinduced intestinal injury in rats. Nutrition 2006; 22:179-186.
16. Ki Y, Kim W, Cho H, et al. The effect of probiotics for preventing radiationinduced morphological changes in intestinal mucosa of rats. J Korean Med Sci 2014; 29:1372-1378.
17. Ciorba MA, Riehl TE, Rao MS, et al. Lactobacillus probiotic protects intestinal epithelium from radiation injury in a TLR-2/cyclo-oxygenase-2-dependent manner. Gut 2012; 61:829-838.
18. Ciorba MA, Stenson WF. Probiotic therapy in radiation-induced intestinal injury and repair. Ann N Y Acad Sci 2009; 1165:190-194.
19. Lalla RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120:1453-1461.
20. Chitapanarux I, Chitapanarux T, Traisathit P, et al. Randomized controlled trial of live lactobacillus acidophilus plus bifidobacterium bifidum in prophylaxis of diarrhea during radiotherapy in cervical cancer patients. Radiat Oncol 2010; 5:31.
21. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. World J Gastroenterol 2007; 13: 912-915.
22. Delia P, Sansotta G, Donato V, et al. Use of probiotics for prevention of radiation-induced diarrhea. Tumori 2007; 93:1-6; suppl.
23. Demers M, Dagnault A, Desjardins J. A randomized double-blind controlled trial: impact of probiotics on diarrhea in patients treated with pelvic radiation. Clin Nutr 2014; 33:761-767.
24. Giralt J, Regadera JP, Verges R, et al. Effects of probiotic Lactobacillus casei DN-114 001 in prevention of radiation-induced diarrhea: results from multicenter, randomized, placebo-controlled nutritional trial. Int J Radiat Oncol Biol Phys 2008; 71:1213-1219.
25. Lacouture ME, Keefe DM, Sonis S, et al. A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer. Ann Oncol 2016; 27:1712-1718.
26. Mego M, Chovanec J, Vochyanova-Andrezalova I, et al. Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study. Complement Ther Med 2015; 23: 356-362.
27. Osterlund P, Ruotsalainen T, Korpela R, et al. Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. Br J Cancer 2007; 97:1028-1034.
28. Delia P, Sansotta G, Donato V, et al. Prevention of radiation-induced diarrhea with the use of VSL#3, a new high-potency probiotic preparation. Am J Gastroenterol 2002; 97:2150-2152.
29. Liu MM, Li ST, Shu Y, Zhan HQ. Probiotics for prevention of radiation-induced diarrhea: a meta-analysis of randomized controlled trials. PLoS One 2017; 12:e0178870.
30. Wang YH, Yao N, Wei KK, et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr 2016; 70:1246-1253.
31. Fuccio L, Guido A, Eusebi LH, et al. Effects of probiotics for the prevention and treatment of radiation-induced diarrhea. J Clin Gastroenterol 2009; 43:506-513.
32. Castro MG, Glasberg SP, Horie LM, Waitzberg DL. Effects of probiotic in prevention of radiation-induced diarrhea. Clin Nutr Suppl 2009; 4:72-73.
33. Okawa T, Niibe H, Arai T, et al. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix-a phase-III, multicenter, randomized, controlled-study. Cancer 1993; 72:1949-1954.
34. Sterne JA, Gavaghan D, Egger M. Publication and related bias in metaanalysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000; 53:1119-1129.
35. Lacouture ME. authors of the publication ApIIsteptod-id, gastrointestinal adverse events in advanced nonsmall-cell lung c. reply to the letter to the editor 'Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced nonsmall-cell lung cancer enrolled in ARCHER-1042 trial' by Ceccarelli et al. Ann Oncol 2016; 27:2138-2139.
36. Van Sebille YZA, Gibson RJ, Wardill HR, et al. Dacomitinib-induced diarrhoea is associated with altered gastrointestinal permeability and disruption in ileal histology in rats. Int J Cancer 2017; 140:2820-2829.
37. Ceccarelli G, Schietroma I, Corano Scheri G, et al. Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced nonsmallcell lung cancer enrolled in ARCHER-1042 trial. Ann Oncol 2016; 27:2137-2138.
38. Manichanh C, Varela E, Martinez C, et al. The gut microbiota predispose to the pathophysiology of acute postradiotherapy diarrhea. Am J Gastroenterol 2008; 103:1754-1761.
39. Wardill HR, Tissing WJE. Determining risk of severe gastrointestinal toxicity based on pretreatment gut microbial community in patients receiving cancer treatment: a new predictive strategy in the quest for personalized cancer medicine. Curr Opin Support Palliat Care 2017; 11:125-132.
40. Covington JA, Wedlake L, Andreyev J, et al. The detection of patients at risk of gastrointestinal toxicity during pelvic radiotherapy by electronic nose and FAIMS: a pilot study. Sensors (Basel) 2012; 12: 13002-13018.
41. Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun 2016; 7:10391.
42. Roy S, Trinchieri G. Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 2017; 17:271-285.
43. Wedlake L, Shaw C, McNair H, et al. Randomized controlled trial of dietary fiber for the prevention of radiation-induced gastrointestinal toxicity during pelvic radiotherapy. Am J Clin Nutr 2017; 106:849-857.